Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Box 100245, Gainesville, FL 32610-0245, USA.
J Neurooncol. 2011 Feb;101(3):429-40. doi: 10.1007/s11060-010-0277-7. Epub 2010 Jul 3.
Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5' flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.
转谷氨酰胺酶 2(TG2)是一种广泛表达的蛋白质,能够催化蛋白质/蛋白质的交联。由于细胞外 TG2 交联细胞外基质的成分,因此认为 TG2 作为细胞侵袭的抑制剂发挥作用。我们最近发现,转谷氨酰胺酶 2 基因(TGM2)是乳腺癌中表观遗传沉默的靶标,突出了驱动 TG2 表达降低的分子机制,这种异常的分子事件可能导致这种肿瘤类型的侵袭性。由于肿瘤的侵袭性是脑肿瘤侵袭性的主要决定因素,我们试图确定 TGM2 是否在神经胶质瘤中被靶向进行表观遗传沉默。在一系列培养的人神经胶质瘤细胞中分析 TGM2 基因甲基化表明,TGM2 基因的 5'侧翼区高度甲基化,并且通过免疫印迹判断,这种特征与 TG2 表达降低有关。此外,在存在全局 DNA 去甲基化剂 5-氮杂-2'-脱氧胞苷和组蛋白去乙酰化酶抑制剂 Trichostatin A 的情况下培养神经胶质瘤细胞导致这些细胞系中 TG2 的重新表达。在原发性脑肿瘤中,我们观察到 TGM2 启动子通常高度甲基化,并且这种特征是癌症相关的现象。使用公共可用的数据库,发现神经胶质瘤中的 TG2 表达差异很大,许多肿瘤表现出该基因的过表达或低表达。由于 TG2 的过表达通过异位激活 NFκB 导致对阿霉素的耐药性,因此我们试图检查重组 TG2 在接受常用脑肿瘤治疗药物治疗的神经胶质瘤细胞中的表达对 TG2 的影响。我们观察到,除了阿霉素外,TG2 表达还导致对 CCNU 的耐药性;然而,TG2 表达并没有改变对其他测试药物的敏感性。最后,TG2 的催化无效突变体也能够支持神经胶质瘤细胞中的阿霉素耐药性,表明转谷氨酰胺酶活性对于耐药表型不是必需的。